To evaluate the efficacy and safety of once-weekly DPP-4 inhibitor: Omarigliptin and the differences between Omarigliptin and once or twice-daily DPP-4 inhibitors for the treatment of type 2 diabetes
Not Applicable
- Conditions
- type 2 diabetes
- Registration Number
- JPRN-UMIN000029288
- Lead Sponsor
- Diabetes Internal Medicine, Tohto Clinic
- Brief Summary
Omarigliptin tended to elicit reductions in FBG, LDL-C, TG, AST, ALT, gamma-GTP, ACR with log ACR, and SBP and DBP, but the differences did not reach statistical significance compared with control. Values for HDL-C tended to increase, but also did not reach statistical significance compared with control. Omarigliptin significantly decreased HOMA-IR, RLP-C, and hsCRP with log hsCRP compared with control. However, omarigliptin did not affect HbA1c, BMI, and eGFR.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 84
Inclusion Criteria
Not provided
Exclusion Criteria
1)eGFR<30 2)Having had side effects of another DPP-4inhibitors before
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method